<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857372</url>
  </required_header>
  <id_info>
    <org_study_id>CIAG933A12101</org_study_id>
    <nct_id>NCT04857372</nct_id>
  </id_info>
  <brief_title>A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors</brief_title>
  <official_title>An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and tolerability of IAG933 in&#xD;
      patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ&#xD;
      fusions and to identify the maximum tolerated dose and/or recommended dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, open-label, multi-center study of IAG933 as a single agent consisting of a&#xD;
      dose escalation part, followed by a dose expansion part. The escalation part will&#xD;
      characterize the safety and tolerability. After the determination of the recommended&#xD;
      dose/maximum tolerated dose, dose expansion will assess the preliminary anti-tumor activity&#xD;
      in defined patient populations and further assess the safety and tolerability at RD/MTD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">May 23, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events and serious adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Safety and tolerability of IAG933</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities during the first treatment cycle (dose escalation only)</measure>
    <time_frame>1 year</time_frame>
    <description>Safety, tolerability and the maximum tolerated dose or recommended dose of IAG933</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with dose interruptions and dose changes</measure>
    <time_frame>3 years</time_frame>
    <description>Tolerability of IAG933</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>3 years</time_frame>
    <description>Assess anti-tumor activity as per RECIST v1.1 and mRECIST v1.1 (for the malignant pleural mesothelioma patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>3 years</time_frame>
    <description>Assess anti-tumor activity as per RECIST v1.1 and mRECIST v1.1 (for the malignant pleural mesothelioma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Assess anti-tumor activity as per RECIST v1.1 and mRECIST v1.1 (for the malignant pleural mesothelioma patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>3 years</time_frame>
    <description>Assess anti-tumor activity as per RECIST v1.1 and mRECIST v1.1 (for the malignant pleural mesothelioma patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (dose expansion only)</measure>
    <time_frame>3 years</time_frame>
    <description>Assess anti-tumor activity as per RECIST v1.1 and mRECIST v1.1 (for the malignant pleural mesothelioma patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum serum concentration (Cmin) (dose escalation only)</measure>
    <time_frame>1 year</time_frame>
    <description>Characterize PK of IAG933</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>3 years</time_frame>
    <description>Characterize PK of IAG933</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>3 years</time_frame>
    <description>Characterize PK of IAG933</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>3 years</time_frame>
    <description>Characterize PK of IAG933</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T1/2) (dose escalation only)</measure>
    <time_frame>1 year</time_frame>
    <description>Characterize PK of IAG933</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Racc) (dose escalation only)</measure>
    <time_frame>1 year</time_frame>
    <description>Characterize PK of IAG933</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Malignant pleural mesothelioma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NF2 truncating mutations or deletions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solid tumors with functional YAP/TAZ fusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IAG933</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent must be obtained prior to participation in the study.&#xD;
&#xD;
          2. Male or female patients must be â‰¥ 18 years of age.&#xD;
&#xD;
          3. Dose escalation part: patients with histologically or cytologically confirmed&#xD;
             diagnosis of advanced (unresectable or metastatic) mesothelioma or other solid tumors.&#xD;
             Patients with solid tumors other than mesothelioma must have local available data for&#xD;
             loss-of-function NF2/LATS1/LATS2 genetic alterations (truncating mutation or gene&#xD;
             deletion; LATS1/LATS2 mutations will only be included in the dose escalation part), or&#xD;
             functional YAP/TAZ fusions. Patients with malignant EHE can be enrolled with only&#xD;
             histological confirmation of the disease. Patients must have failed available standard&#xD;
             therapies, be intolerant of or ineligible for standard therapy, or for whom no&#xD;
             standard therapy exists.&#xD;
&#xD;
          4. Dose expansion part: the following patients will be enrolled into 3 different&#xD;
             treatment groups:&#xD;
&#xD;
             Group 1: Advanced (unresectable or metastatic) MPM patients who have failed available&#xD;
             standard therapies for advanced/metastatic disease, be intolerant or ineligible to&#xD;
             receive such therapy, or for whom no standard therapy exists.&#xD;
&#xD;
             Group 2: Advanced (unresectable or metastatic) solid tumor patients with available&#xD;
             local data for NF2 truncating mutation or deletions. Patient must have failed&#xD;
             available standard therapies, be intolerant or ineligible to receive such therapy, or&#xD;
             for whom no standard therapy exists.&#xD;
&#xD;
             Group 3: Advanced (unresectable or metastatic) solid tumor patients with available&#xD;
             local data for functional YAP/TAZ fusions. EHE patients can be included with only&#xD;
             histological confirmation of the disease. Patient must have failed available standard&#xD;
             therapies, be intolerant or ineligible to receive such therapy, or for whom no&#xD;
             standard therapy exists.&#xD;
&#xD;
          5. Presence of at least one measurable lesion according to mRECIST v1.1 for mesothelioma&#xD;
             patients, RECIST v1.1 for patients with other solid tumors, or RANO for patients with&#xD;
             primary brain tumors.&#xD;
&#xD;
          6. Patient must have a site of disease amenable to biopsy and be a candidate for tumor&#xD;
             biopsy according to the treating institution's guidelines. Patient must be willing to&#xD;
             undergo a new tumor biopsy at screening/baseline, and again during therapy on this&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with any of the following anti-cancer therapies prior to the first dose of&#xD;
             study treatment within the stated timeframes:&#xD;
&#xD;
               1. â‰¤ 4 weeks for thoracic radiotherapy to lung fields or limited field radiation for&#xD;
                  palliation within â‰¤ 2 weeks prior to the first dose of study treatment. An&#xD;
                  exception to this exists for patients who have received palliative radiotherapy&#xD;
                  to bone, who must have recovered from radiotherapy-related toxicities but for&#xD;
                  whom a 2-week washout period is not required.&#xD;
&#xD;
               2. â‰¤ 4 weeks or â‰¤ 5 half-lives (whichever is shorter) for chemotherapy or biological&#xD;
                  therapy (including monoclonal antibodies) or continuous or intermittent small&#xD;
                  molecule therapeutics or any other investigational agent.&#xD;
&#xD;
               3. â‰¤ 6 weeks for cytotoxic agents with risk of major delayed toxicities, such as&#xD;
                  nitrosoureas and mitomycin C.&#xD;
&#xD;
               4. â‰¤ 4 weeks for immuno-oncologic therapy, such as CTLA4, PD-1, or PD-L1 antagonists&#xD;
&#xD;
          2. For mesothelioma patients: use of non-invasive antineoplastic therapy (e.g., tumor&#xD;
             treating fields, brand name Optune LuaTM) within 2 weeks of the tumor assessment at&#xD;
             screening.&#xD;
&#xD;
          3. Malignant disease, other than that being treated in this study.&#xD;
&#xD;
          4. Insufficient renal function at Screening.&#xD;
&#xD;
          5. Clinically significant cardiac disease or risk factors at screening&#xD;
&#xD;
          6. Insufficient bone marrow function at screening.&#xD;
&#xD;
          7. Insufficient hepatic function at screening.&#xD;
&#xD;
          8. Patients who have the following laboratory values outside of the laboratory normal&#xD;
             limits:&#xD;
&#xD;
               1. Potassium&#xD;
&#xD;
               2. Magnesium&#xD;
&#xD;
               3. Total calcium (corrected for low serum albumin)&#xD;
&#xD;
          9. Known active COVID-19 infection.&#xD;
&#xD;
         10. Pregnant or nursing (lactating) women,&#xD;
&#xD;
         11. Japan only: patients with a history of drug- and/or non-drug-induced interstitial lung&#xD;
             disease (ILD) â‰¥ Grade 2.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104 0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Japan</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesothelioma</keyword>
  <keyword>IAG933</keyword>
  <keyword>NF2 mutated tumors</keyword>
  <keyword>LATS1/LATS2 mutated tumors</keyword>
  <keyword>YAP/TAZ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

